Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry researchers · Friday, March 29, 2024 · 699,655,451 Articles · 3+ Million Readers

Respinova Wins Chiesi Spain and Richi Entrepreneurs Second Call

BARCELONA, Spain, July 19, 2018 (GLOBE NEWSWIRE) -- Respinova, a Herzliya, Israel-based clinical-stage medical device company developing the novel, non-invasive PulseHalerä technology, today announced that it has won the second grant offered by Chiesi Spain and Richi Entrepreneurs to promote an innovative project that directly impacts treatment and quality of life of patients with chronic obstructive pulmonary disease (“COPD”). As such, two members of Respinova will participate in the Boston Immersion Program of Richi Entrepreneurs.

Barcelona Photo
The five startups finalists of the call, and the members of Chiesi and Richi Entrepreneurs teams.


Richi Entrepreneurs


Chiesi


The PulseHalerä device delivers proprietary pulses of pressure to facilitate the intake of inhaled medication by creating multiple momentary dilating forces that gently pry open collapsed airways, generate positive pressure on exhalation, and smooth the mucus lining layer to clear airways and reduce the tendency to re-close. The technology has been clinically demonstrated to improve exercise capacity, lung function, and quality of life for COPD patients.

“We are extremely proud and honored to have been chosen by Chiesi as the winners of the call,” said Cliff Ansel, CEO of Respinova. “The scholarship to the Boston Innovation Program will allow us to experience one of the leading health-tech ecosystems first hand.”

“With this grant, Chiesi Spain intends to promote and support the formation of Respinova in an entrepreneurial environment where they can make first-rate contacts in a city considered the first world ecosystem in biotechnology, medtech and digital health,” said Giuseppe Chiericatti, General Manager of Chiesi Spain. “The search for effective and innovative solutions for the treatment of respiratory diseases is one of Chiesi’s main commitments.”

“The great thing about this collaboration is that it allows us to support startups with a high impact on health, while also contributing to Chiesi's open innovation strategy,” said Ernest Lara, Executive Director of Richi Entrepreneurs. “In this second edition, 20 startups from 12 countries registered for the call. We are very happy with the quality and professionalism of the five finalist startups, including four medical devices and a biotech, from Israel, Turkey, France, Iceland, and UK.”

The Chiesi Spain and Richi Entrepreneurs collaboration is aimed at startups around the world that have a direct relationship with one of the pharmaceutical company’s main therapeutic areas: respiratory, neonatology, rare diseases, transplants and consumer healthcare.

The selection of Respinova was the result of a vote by all employees of Chiesi Spain who had the opportunity to assess each of the projects under a series of parameters aligned to the company’s strategy, in a presentation of the five projects finalists, on June 29, 2018.

This initiative was born in 2016 as a result of the commitment of Chiesi Spain and Richi Entrepreneurs to the cultural exchange, innovation and entrepreneurship applied to the search for innovative therapeutic solutions. In the first call, projects were received from seven countries in Europe and the United States, within all the therapeutic areas of Chiesi. The grant went to startup, New Born Solutions, and its project for the development of NeoSonics, the first non-invasive scanning device for the detection of childhood meningitis.

About Chiesi

Chiesi Spain is part of Chiesi Farmaceutici, a pharmaceutical company based in Parma, Italy, created more than 80 years ago. In recent years, its policy of promoting R&D and new acquisitions has made it possible to achieve sales of around more than 1,571 million €. It has three production plants in Italy, France, and Brazil, and five research centers in Italy, France, Great Britain, Sweden, and the United States, and employs over 5600 people globally. It has a strong presence in Europe, America and Asia. Chiesi Spain currently has more than 260 employees and a turnover of more than € 99M. For more information visit www.chiesi.es or follow us @Chiesi_es.

About Richi Entrepreneurs

Richi Entrepreneurs is a Richi Foundation initiative whose mission is to boost life sciences - biotech, medtech, digital health, and cleantech startups from around the world by connecting them with Boston’s innovation key players and helping them take full advantage of this unique innovation ecosystem. Richi Entrepreneurs does so by running a three-week immersion boot camp in Boston, in which startups have the opportunity to embrace best practices from the Massachusetts ecosystem, connecting and interacting with potential clients, investors, strategic partners, and local top-notch industry experts who will lead them to outstanding synergies. More information about Richi Entrepreneurs is available at https://www.richientrepreneurs.org or follow @RichiE_RCCF. 

About Richi Childhood Cancer Foundation

The Richi Childhood Cancer Foundation (Richi Foundation) is a nonprofit organization whose mission is to ensure that all children who suffer from cancer have the best prognosis and quality of life. All proceeds from Richi Entrepreneurs will go to support the Richi Foundation mission. More information is available at https://www.richifoundation.org

About Respinova

Respinova Ltd., a Herzliya, Israel-based, clinical-stage medical device company, is developing the PulseHaler™ technology for the treatment of COPD and other respiratory diseases. The PulseHaler™ technology has been clinically demonstrated to improve exercise capacity, lung function, and quality of life for COPD patients. For more information visit www.respinova.com.

Contact:

Respinova
Ishay Attar, VP Business Development
ishay@respinova.com +972 54-812-2044

Chiesi
Rosa Horri, Communication
r.horri@chiesi.com +34 664 810 017 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7a29db7c-a060-4c65-898b-f019a3a58add

Primary Logo

Powered by EIN News
Distribution channels: Healthcare & Pharmaceuticals Industry


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release